Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
NCT ID: NCT01981473
Last Updated: 2016-01-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
605 participants
OBSERVATIONAL
2014-01-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
NCT00796705
Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients
NCT04428424
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT03414502
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
NCT01578850
Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate
NCT01783015
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
etanercept
Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
no intervention
adalimumab
Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
no intervention
infliximab
Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
no intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
no intervention
no intervention
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of RA based on the 1987 American College of Rheumatology revised criteria
3. Current continuous treatment with either etanercept, adalimumab, or infliximab for a minimum of 6 months and maximum of 24 months.
Exclusion Criteria
2. Treatment with any other investigational drugs within past 3 months or five half lives of the drug, whichever is longer.
3. Any medical condition that would interfere with rheumatoid arthritis evaluation or other study assessments (eg, fibromyalgia, lupus).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Arthritis & Rheumatology
Glendale, Arizona, United States
Arizona Arthritis & Rheumatology Associates, P. C.
Mesa, Arizona, United States
Arizona Arthritis & Rheumatology
Phoenix, Arizona, United States
Arizona Arthritis and Rheumatology Research, PLLC
Phoenix, Arizona, United States
Arizona Arthritis & Rheumatology Research
Sun City, Arizona, United States
Mercy Clinic Hot Springs Communities
Hot Springs, Arkansas, United States
Sutter Institute for Medical Research
Sacramento, California, United States
Arthritis Care Center, Incorporated
San Jose, California, United States
Rheumatology Consultants of Delaware dba Delaware Arthritis
Lewes, Delaware, United States
Omega Research Consultants, LLC
DeBary, Florida, United States
Center for Rheumatology, Immunology, and Arthritis
Fort Lauderdale, Florida, United States
Florida Medical Research
Gainesville, Florida, United States
Arthritis and Rheumatic Care Center
South Miami, Florida, United States
Health Point Medical Group, Inc.
Tampa, Florida, United States
Northeast Georgia Diagnostic Clinic, LLC
Gainesville, Georgia, United States
Via Christi Hospitals Wichita, Inc.
Wichita, Kansas, United States
Rheumatology Associates of Baltimore
Baltimore, Maryland, United States
Phase III Clinical Research
Fall River, Massachusetts, United States
David S. Rosenberg, M.D
Florissant, Missouri, United States
Dr Melvin Albert Churchill Jr
Lincoln, Nebraska, United States
Prospect Medical Offices
Midland Park, New Jersey, United States
Advanced Arthritis Care Center
Brooklyn, New York, United States
Prem C.Chatpar, M.D., LLC
Plainview, New York, United States
Box Arthritis and Rheumatology
Charlotte, North Carolina, United States
Clinical Research Center of Reading, LLC
Wyomissing, Pennsylvania, United States
Low Country Rheumatology, PA
North Charleston, South Carolina, United States
Comprehensive Rheumatology Care
Hendersonville, Tennessee, United States
Elizabeth Marini Simpson
Hixon, Tennessee, United States
Austin Regional Clinic
Austin, Texas, United States
Accurate Clinical Research
Houston, Texas, United States
Clinical Research Institute of Houston
Houston, Texas, United States
Spring Clinical Research
Tomball, Texas, United States
Center for Arthritis and Rheumatic Diseases, P.C.
Chesapeake, Virginia, United States
Arthritis Northwest, PLLC
Spokane, Washington, United States
Hospital Británico de Buenos Aires
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Sociedad Italiana de Beneficencia en Buenos Aires (Hospital Italiano de Buenos Aires)
Ciudad Autónoma de Buenos Aires / Buenos Aires, Buenos Aires / Argentina, Argentina
Instituto de Asistencia Reumatológica Integral I.A.R.I
San Fernando, Buenos Aires / Argentina, Argentina
Clínica Adventista Belgrano
Ciudad Autónoma de Buenos Aires / Buenos Aires, Ciudad Autónoma de Buenos Aires / Buenos Aires /Argentina., Argentina
CIER, centro de investigaciones en enfermedades reumáticas (Razón social: ARIES MEDICA S.R.L.)
Ciudad de Buenos Aires / Buenos Aires, Ciudad de Buenos Aires, Buenos Aires, Argentina, Argentina
Sociedad Española de Beneficiencia y Mutualidad Hospital español de Mendoza
Godoy Cruz, Mendoza / Argentina, Argentina
DIM Clinica Privada
Ramos Mejía, Ramos Mejía / Buenos Aires / Argentina, Argentina
Centro Integral de Reumatología S.R.L.
S.M. de Tucumán / Tucumán, S.M. de Tucumán / Tucumán / Argentina., Argentina
C.E.R - Centro Polivalente de Asistencia e Investigación Clínica propiedad de CER SAN JUAN S.R.L.
San Juan, San Juan / San Juan / Buenos Aires, Argentina
Instituto CAICI SRL.
Rosario, Santa Fe / Argentina, Argentina
I.N.Ne.L S.R.L. (Instituto de Neurología y Neurorrehabilitación del Litoral S.R.L.)
Santa Fé, Santa Fé / Argentina, Argentina
Southern Clinical Research Pty Ltd
Sandy Bay, Hobart, Tasmania, Australia
MHAT Burgas
Burgas, , Bulgaria
DCC Sveti Pantaleimon OOD
Pleven, , Bulgaria
MHAT Kaspela EOOD
Plovdiv, , Bulgaria
UMHAT "Sv.Ivan Rilski"
Sofia, , Bulgaria
Cukurova Universitesi Tip Fakultesi Balcalı Hastanesi
Adana, , Turkey (Türkiye)
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, , Turkey (Türkiye)
Ataturk Universitesi Yakutiye Egitim ve Arastirma Hastanesi
Erzurum, , Turkey (Türkiye)
Osmangazi Universitesi Tıp Fakultesi Hastanesi
Eskişehir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bassiouni H, Spargo CE, Vlahos B, Jones HE, Pedersen R, Shirazy K. Maintenance of Remission with Etanercept-DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis. Rheumatol Ther. 2018 Jun;5(1):149-158. doi: 10.1007/s40744-018-0094-6. Epub 2018 Feb 26.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANTIBODY-RA
Identifier Type: OTHER
Identifier Source: secondary_id
B1801364
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.